乌司奴单抗治疗肛周克罗恩病:GETAID的BioLAP多中心研究
该全国多中心回顾性队列纳入207例肛周克罗恩病患者,多数既往暴露于抗TNF。活动性肛周病变患者6个月临床成功率为38.5%,起始带挂线者33%成功移除挂线;非优化治疗与成功相关(P=0.044)。非活动性患者26周和52周无复发生存概率分别为86.2%和75.1%。
要点
- 活动性肛周克罗恩病6个月临床成功率为38.5%(57/148)。
- 起始带挂线患者中33%(29/88)成功移除挂线。
- 非活动性患者52周无复发生存概率为75.1%。
核心结论
- 乌司奴单抗似乎是难治性肛周克罗恩病潜在有效的治疗选择。
- 需要进一步的前瞻性研究。
研究设计与样本
- 全国多中心回顾性队列研究,纳入207例接受乌司奴单抗的活动性或非活动性肛周克罗恩病患者。
- 平均年龄37.7岁,平均克罗恩病病程14.3年,平均既往肛周手术次数2.8次。
- 205例(99%)既往暴露于至少1种抗TNF药物,58例(28%)既往暴露于维得利珠单抗。
- 中位随访时间48周。
主要发现
- 56/207例(27%)患者在中位43周后停用治疗。
- 活动性肛周病变患者中,57/148例(38.5%)达到6个月临床成功。
- 起始带挂线患者中,29/88例(33%)成功移除挂线。
- 非活动性肛周病变患者26周和52周无复发生存概率分别为86.2%和75.1%。
关键数值与推荐
- 活动性肛周病变患者6个月临床成功定义为医生判断临床成功且未因肛周病变追加药物或手术治疗。
- 未优化治疗与治疗成功相关(P=0.044,比值比2.74;95%置信区间:0.96-7.82)。
- 多因素分析中,既往抗TNF药物数量≥3种为边缘显著(P=0.056,比值比0.4;95%置信区间:0.15-1.08)。
临床怎么用
- 乌司奴单抗似乎可作为难治性肛周克罗恩病的潜在有效治疗选择。
- 非优化治疗与治疗成功相关(P=0.044,比值比2.74;95%置信区间:0.96-7.82)。
- 既往抗TNF药物数量≥3种与治疗成功的关系为边缘显著(P=0.056,比值比0.4;95%置信区间:0.15-1.08)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: New therapeutic options for patients with Crohn's disease (CD) with perianal lesions failing anti-tumor necrosis factor (TNF) agents are needed. We aimed to assess the effectiveness of ustekinumab in perianal CD (pCD) and predictors of clinical success in a real-life multicenter cohort. METHODS: We conducted a national multicenter retrospective cohort study in patients with either active or inactive pCD who received ustekinumab. In patients with active pCD at treatment initiation, the success of ustekinumab was defined by clinical success at 6 months assessed by the physician's judgment without additional medical or surgical treatment for pCD. Univariate and multivariable logistic regression analyses were performed to identify predictors of success. In patients with inactive pCD at ustekinumab initiation, the pCD recurrence-free survival was calculated using the Kaplan-Meier method. RESULTS: Two hundred seven patients were included, the mean age was 37.7 years, the mean duration of CD was 14.3 years, and the mean number of prior perianal surgeries was 2.8. Two hundred five (99%) patients had previously been exposed to at least 1 anti-TNF and 58 (28%) to vedolizumab. The median follow-up time was 48 weeks; 56/207 (27%) patients discontinued therapy after a median time of 43 weeks. In patients with active pCD, success was reached in 57/148 (38.5%) patients. Among patients with setons at initiation, 29/88 (33%) had a successful removal. The absence of optimization was associated with treatment success (P = 0.044, odds ratio 2.74; 95% confidence interval: 0.96-7.82). In multivariable analysis, the number of prior anti-TNF agents (≥3) was borderline significant (P = 0.056, odds ratio 0.4; 95% confidence interval: 0.15-1.08). In patients with inactive pCD at initiation, the probability of recurrence-free survival was 86.2% and 75.1% at weeks 26 and 52, respectively. DISCUSSION: Ustekinumab appears as a potential effective therapeutic option in perianal refractory CD. Further prospective studies are warranted.
引用
- Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. Am J Gastroenterol. 2020. PMID: 33156100. doi:10.14309/ajg.0000000000000810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。